EGFR and metastasis: In conclusions, this retrospective study suggests that for the patients, treated with EGFR‐TKIs ≥6 months, EGFR exon 19 del, osteogenic bone metastasis, bisphosphonate application times ≥6, smoking <400/day and the number of BM <3 were predictors of better OS (p < .05).